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Akira Isaka4, Ayako Osawa4, Masahiro Terada4 and Koichi Mikami4
Background: 1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) has been shown to
modulate not only proliferation and differentiation, but also apoptosis in
malignant cells, indicating that it could be useful for treating cancer. Little
information is available concerning the structural motifs of the 1α,25(OH)2D3
molecule responsible for modulation of differentiation and apoptosis, however.
We set out to synthesize singly dehydroxylated A-ring analogs of 19-nor-
1α,25(OH)2D3 in a catalytic asymmetric fashion, and to investigate their
biological activities in leukemia HL-60 cells.
Results: A series of singly dehydroxylated 19-nor-1α,25-dihydroxyvitamin D3
A-ring analogs were synthesized using a combinatiorial sequence of
regioselective propiolate-ene reaction and catalytic asymmetric carbonyl-ene
cyclization. Surprisingly, the analogs could be clearly divided into two
categories; one group, bearing 1α-hydroxy or 3β-hydroxy groups in the A-ring,
were potent differentiators and the second group, bearing 1β-hydroxy or 3α-
hydroxy groups, were potent stimulators of apoptosis.
Conclusions: We have clearly identified the structural motifs of
19-nor-1α,25(OH)2D3 analogs responsible for differentiation and apoptosis in
HL-60 cells. These findings will provide useful information not only for
development of therapeutic agents for treatment of leukemia and other cancers,
but also for structure–function studies of 1α,25(OH)2D3.
Introduction
The hormonally active form of vitamin D3, 1α,25-dihydrox-
yvitamin D3 (1α,25(OH)2D3) [1], has been recognized as a
potent regulator of calcium homeostasis and bone growth. It
is also a potent differentiator of immature hematopoietic
cells [2] and a potent growth inhibitor of various types of
cancer cells, including breast [3], prostate [4] and colon [5],
although the sensitivity of prostate cancer cells to the
antiproliferative effects of 1α,25(OH)2D3 varies [6]. These
observations have suggested a potential therapeutic appli-
cation of this hormone in cancer, acute promyelocytic
leukemia and psoriasis [7–9]. The mechanisms of growth
inhibition and cell differentiation activities and the basis for
the variability in antiproliferative effects of 1α,25(OH)2D3
on certain malignant cells, such as breast [10] and prostate
cancer cells [11], is not understood, however. Biological
activities of 1α,25(OH)2D3 are predominantly expressed
through a transcriptional regulation resulting from the inter-
action of 1α,25(OH)2D3 with the vitamin D receptor (VDR)
[12], which is a member of the superfamily of nuclear
receptors [13], similar to the thyroid hormone receptor [14],
retinoic acid receptor [15], estrogen receptor [16] and gluco-
corticoid receptor [17]. The 1α,25(OH)2D3-liganded VDR
forms a heterodimer with the retinoid X receptor (RXR)
[18,19], which binds to specific DNA sequences,
vitamin D-responsive elements (VDREs), to induce tran-
scription [20,21]. An ideal analog of 1α,25(OH)2D3 would,
therefore, possess a high binding affinity for VDR, be able
to form a stable VDR–RXR complex and bind strongly to
VDREs. From extensive structure–function studies of the
vitamin D molecule, it has been assumed that both the
hydroxy groups at C-1 and C-25, and possibly the hydroxyl
group at C-3, are essential for binding to VDR, which in
turn results in expression of the hormonal activities [22].
However, Boehm et al. [23] recently reported that a nonsec-
osteroidal vitamin D analog, 2′-[4-(2-hydroxy-3,3-dimethyl-
butoxy)-3-methylphenyl]-2′-[4-(2,3-dihydroxypropoxy)-3-
methyphenyl]pentane (LG190178), exerts VDR-modulat-
ing activities at the molecular level, as well as in vivo.
DeLuca and coworkers [24] have reported that 19-nor
analogs of 1α,25(OH)2D3, in which an exocyclic methylene
group at C-10 on the A-ring is replaced by two hydrogen
atoms, have selective activity profiles that combine a high
potency for inducing differentiation of malignant
cells with very low or nonexistent bone calcitropic 
activity. Furthermore, 1α,2α,25-trihydroxy-19-nor-vitamin
Addresses: 1Department of Hygienic Sciences,
Kobe Pharmaceutical University, Kobe 658-8558,
Japan. 2Chugai Pharmaceutical Co. Ltd, Tokyo
104-8301, Japan. 3Department of Environmental
Medicine, Research Institute, Osaka Medical Center
for Maternal and Child Health, Osaka 594-1101,
Japan. 4Department of Chemical Technology, Tokyo
Institute of Technology, Tokyo 152-8552, Japan.
Correspondence: Toshio Okano and Koichi Mikami
E-mail: t-okano@kobepharma-u.ac.jp
kmikami@mail-o.cc.titech.ac.jp
Key words: apoptosis, asymmetric catalysis,
cancer-cell differentiation, carbonylene reaction,
singly dehydroxylated A-ring analogs of
19-nor-1α,25(OH)2D3
Received: 25 October 1999
Accepted: 15 November 1999
Published: 18 February 2000
Chemistry & Biology 2000, 7:173–184
1074-5521/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
Research Paper 173
cm7307.qxd  03/10/2000  11:31  Page 173
D3, 1α,2β,25-trihydroxy-19-nor-vitamin D3 and their
2-alkoxy analogs have been shown to exhibit selective activ-
ity in stimulating intestinal calcium transport while having
little or no involvement in mobilizing bone calcium [25].
The elucidation of the possible roles of the 1α-hydroxy
group, 3β-hydroxy group, and an exocyclic methylene group
at C-10 on the A-ring of 1α,25(OH)2D3 might, therefore,
lead to the development of new drugs that are useful for
treating cancer and immune diseases. We previously evalu-
ated the biological activities of both series of 19-nor-22-oxa-
1α,25(OH)2D3 and singly dehydroxylated A-ring analogs of
19-nor-1α,25(OH)2D3 with respect to binding affinities for
VDR and vitamin D binding protein (DBP) and transactiva-
tion on a rat 25-hydroxyvitamin D3-24-hydroxylase gene
promotor, which has two VDREs, in transfected rat osteosar-
coma ROS 17/2.8 cells [26,27]. Surprisingly, several 19-nor
analogs were found to be transcriptionally slightly less active
than 1α,25(OH)2D3 or almost comparable to 1α,25(OH)2D3
despite extremely low binding affinities for VDR. To
examine further the biological activity of the 19-nor
analogs, we have now investigated their effects on target
gene expression, cell-cycle distribution, differentiation into 
monocytes/ macrophages and apoptosis in human promyelo-
cytic leukemic HL-60 cells. The results revealed an inverse
relationship between differentiation-inducing activity and
apoptosis-stimulating activity of the 19-nor analogs. One
series of 19-nor analogs with 1α- or 3β-hydroxy groups in the
A-ring induced cell differentiation and promoted cell-cycle
arrest in the G0/G1 phase, but did not stimulate apoptosis.
In contrast, the remaining series of 19-nor analogs with 1β-or
3α-hydroxy groups in the A-ring stimulated apoptosis, but
were inactive in the regulation of cell differentiation and
proliferation. The present findings suggest interesting
potential roles for the 1α- and 3β-hydroxy groups or 1β- and
3α-hydroxy groups in the A-ring in regulating cancer cell dif-
ferentiation or apoptosis, respectively.
Results and discussion
Catalytic asymmetric syntheses of a series of singly
dehydroxylated 19-nor-1α,25-dihydroxyvitamin D3 A-ring
analogs
The syntheses of both series of singly dehydroxylated
19-nor-1α,25-dihydroxyvitamin D3 A-ring analogs
(Figure 1) were established on the basis of our asymmetric
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Figure 1
Chemical structures and names assigned to
the singly dehydroxylated A-ring analogs of
19-nor-1α,25(OH)2D3 and 19-nor-22-
oxa-(1α),25(OH)2D3.
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catalytic carbonyl-ene cyclization [28,29] using a binaph-
thol-derived titanium (BINOL-Ti) complex (1; Figure 2)
[30–32]. The key feature in the syntheses of the A-ring
analogs is the stereospecific transformation of the (E)- and
(Z)-ene cyclization products (3) into the 3-hydroxy and
1-hydroxy A-ring analogs, respectively.
The preparation of the ene-cyclization substrates (2) is
worth mentioning (Figure 3). The ene-cyclization sub-
strate 2 was prepared through the reaction sequence start-
ing from regioselective propiolate-ene reaction of
homoallylic ether (4) [33] with methyl propiolate (5)
using EtAlCl2 as the initiator [34]. The regioselectivities
of the propiolate-ene reaction, namely H- versus H′-shifts
leading to the newly formed olefins 6 and 7, respectively,
critically depend on the steric and electronic effects of
the alcohol-protecting groups (P) employed. It should be
noted here that the sterically highly demanding triiso-
propylsilyl (TIPS) group gave higher (94%) regioselectiv-
ity than those obtained with benzyl (Bn) and
tert-butyldiphenylsilyl (TBDPS) groups. Reduction of the
α,β-unsaturated ester 6, first with magnesium in
methanol and then with lithium aluminum hydride, gave
alcohol 8. The Swern oxidation of alcohol 8 provided the
ene-cyclization substrate, aldehyde 2.
The key step of the syntheses of singly dehydroxylated
19-nor-1α,25-dihydroxyvitamin D3 A-ring analogs was
carried out by tuning the BINOL ligands for the cat-
alytic asymmetric syntheses. The geometrical (Z/E) and
enantioselectivities over the newly formed olefin and
hydroxy groups, respectively, depend critically on the
combination of the BINOL ligands, alcohol-protecting
groups and solvents employed (Table 1). It is notable
that geminal di-alkyl substituents generally required in
the usual catalytic ene cyclization [28,29] are not neces-
sary in the present BINOL-Ti-catalyzed asymmetric car-
bonyl-ene cyclization.
The characteristics of the catalytic asymmetric carbonyl-
ene cyclization in terms of the geometrical and enantiose-
lectivities are shown in Table 1. The carbonyl-ene
cyclization of the TBDPS-protected substrate 2a by the
parent (R)-BINOL-Ti catalyst (5 mol%) in toluene gave
the (Z )-ene cyclization product [(Z )-3)] as the major
product in high enantioselectivity for (S )-1-hydroxy group
(S:R = 95:5; run 1). Even in toluene, the use of the TIPS-
protected substrate 2b provided, in contrast, the
(E)-olefinic isomer (runs 3 and 4). These results suggest
that not only steric but electronic effects of the alcohol-
protecting groups are the determining factors in olefinic
selectivity, in other words, in transition-state conforma-
tions for ene-cyclizations. In the case of the Bn-protecting
group, the (E)-olefinic product, (E)-3c, was obtained as
the major product (runs 5–8). Of importance is that the
use of sterically bulky and electronically withdrawing
6,6′-dibromo-1,1′-bi-2-naphthol (6-Br-BINOL) ligand
[35,36] led to the increase in (E)-geometrical selectivity,
particularly in dichloromethane, along with the high level
of enantioselectivity (S:R = ~95:5). 
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Figure 2
Stereospecific transformation of ene products
(3) obtained via (R )-(6-Br)-BINOL-Ti (1)-
catalyzed asymmetric carbonyl-ene cyclization
to singly dehydroxylated 19-nor-1α,25-
dihydroxyvitamin D3 analogs.
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The enantiomeric excess of the products was determined
by chiral high performance liquid chormatography (HPLC;
DAICEL CHIRALPAK AD, eluent, hexane/propan-2-
ol = 10:1, flow rate 0.5 ml/min, detection 254 nm) and chiral
capillary gas chromatography (CP-cyclodextrin-B-2,3,6-M-
19, 0.32 mm i.d. × 25 m, carrier gas, N2 (1.0 ml/min);
column temp. 155°C; injection temp. 200°C) analyses
and/or by the Mosher method. The absolute configuration
of the products was determined by the Mosher method
after transformation to the corresponding (S)- and (R)-α-
methoxy-α-trifluoromethyl phenylacetyl (MTPA) esters.
The absolute configuration of the newly created stere-
ogenic center at C-1 or C-3 is primarily controlled by the
chirality of the (6-Br)-BINOL-Ti catalysts (1): the (R)-(6-
Br)-BINOL-Ti catalysts (1) lead to the (S)-1- or 3-hydroxy
products. The employment of the enantiomeric catalysts,
(S)-(6-Br)-BINOL-Ti complexes (1), provides the opposite
enantiomers, (1R)- and (3R)-hydroxy A-ring isomers.
The (E/Z)-stereoselectivity of 6-(2,4) [29] carbonyl-ene
cyclization of 2 catalyzed by a (6-Br)-BINOL-Ti complex
(1) depends on the allylic (1,2) strain (TE) and steric repul-
sion with the carbonyl/Lewis acid complex (TZ; Figure 4);
in the ene cyclizations, the carbon numbers where the
tether connects the [1,5]-hydrogen shift system are indi-
cated as (m,n). A numerical prefix, for example 6-(2,4),
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Figure 3
Preparation of ene substrates (2) through
regioselective propiolate-ene reaction.
Reagents and conditions: (i) EtAlCl2,
CH2Cl2, rt; (ii) Mg, MeOH, rt; (iii) LiAlH4,
Et2O, 0°C; (iv) dimethyl sulfoxide (DMSO),
(COCl)2, NEt3, CH2Cl2, –78°C. a, b and c
represent the protecting groups TBDPS,
TIPS and Bn, respectively.
Table 1
Asymmetric carbonyl-ene cyclization catalyzed by (6-Br)-BINOL-Ti complexes (1).
Run 1 2 (OP) Solvent Yield E-3 (% ee):Z-3 (% ee)
1 (R)-BINOL-Ti 2a (OTBDPS) Toluene 88% 37 (76% ee):63 (90% ee)
2 (R)-BINOL-Ti 2a (OTBDPS) CH2Cl2 92% 47 (78% ee):53 (84% ee)
3 (R)-BINOL-Ti 2b (OTIPS) Toluene 71% 59 (77% ee):41 (nd)
4 (R)-(6-Br)-BINOL-Ti 2b (OTIPS) Toluene 68% 62 (85% ee):38 (nd)
5 (R)-BINOL-Ti 2c (OBn) Toluene 55% 61 (85% ee):39 (82% ee)
6 (R)-BINOL-Ti 2c (OBn) CH2Cl2 53% 64 (88% ee):36 (85% ee)
7 (R)-(6-Br)-BINOL-Ti 2c (OBn) Toluene 38% 71 (89% ee):29 (90% ee)
8 (R)-(6-Br)-BINOL-Ti 2c (OBn) CH2Cl2 51% 77 (88% ee):23 (86% ee)
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stands for a (2,4) ene cyclization to give a six-membered
ring. The (E)- and (Z )-alkylidene cyclohexanol products
can be easily separated, however. The carbonyl-ene
cyclization catalyzed by (R)-BINOL-Ti complexes would
proceed via chair-like transition states [37]. The carbonyl-
ene cyclization affords the (E)- and (Z )-isomers of the ene
cyclization product (3) through TZ and TE transition
states, depending on the balance of acyclic allylic strain
with the sterically demanding alcohol-protecting group
(TZ) and repulsion of the bulky (6-Br)-BINOL-Ti catalyst
(TE) with the alkoxymethyl group, respectively. By tuning
the electron withdrawing and sterically demanding (6-Br)-
BINOL ligand [35,36], (E)-geometrical selectivity signifi-
cantly increases, up to 77%, because of the steric repulsion
between the (6-Br)-BINOL-Ti complex and the benzy-
loxy- or siloxy-methyl moieties.
Although (Z)-3 and its geometrical isomer (E)-3 can be
easily separated from each other, they can be transformed,
without separation, to the singly dehydroxylated analogs of
19-nor-1α,25(OH)2D3 (Figure 5), which are also easily sep-
arated from each other. This is because the geometric and
enantiomeric isomers of the ene products (3) can be sepa-
rated as the diastereomers bearing the chiral steroidal C,D
rings at the final stage. On a large scale, the ene-cyclization
product (3) was silylated with dimethylthexylsilyl (TDS)
chloride, without separation, to the (1S)- and (3S)-hydroxy
A-ring intermediates (9). Further transformation of the
intermediate (9) via the chloride (10) gave the Horner–
Emmons–Wittig reagent (11). Lythgoe coupling of the
C,D ring (12: X = CH2 or O) with the Wittig reagent (11)
led (via desilylation) to the singly dehydroxylated analogs
of 19-nor-1α,25(OH)2D3 (Figure 1). After chromatographic
purification, the diastereomerically pure analogs were 
isolated: HPLC (Inertsil SIL, eluent, hexane/ethyl
acetate = 3:1, flow rate 0.5 ml/min) 19-nor(3α):
tR = 24.99 min; 19-nor(3β): tR = 27.43 min; 19-nor(1α):
tR = 30.87 min; 19-nor(1β): tR = 34.55 min, HPLC (Zorbax
SIL, eluent, hexane/2-propanol/methanol = 91:7:2, flow
rate 0.7 ml/min) 19-nor-22-oxa(3α): tR = 12.04 min; 19-nor-
22-oxa(3β): tR = 12.17 min, HPLC (Inertsil SIL, eluent,
hexane/ethyl acetate = 3:1, flow rate 0.8 ml/min) 19-nor-22-
oxa(1α): tR = 13.21 min; 19-nor-22-oxa(1β): tR = 14.24 min.
Transcriptional potencies of 19-nor(3β) and 19-nor-22-oxa(1α)
Transcriptional potencies of 10–8 M 1α,25(OH)2D3 and 19-
nor analogs on HL-60 cells containing the rat 25(OH)D3-24-
hydroxylase gene promoter (which has two VDREs) are
shown in Figure 6. Of the 19-nor analogs, 19-nor(3β) and 19-
nor-22-oxa(1α) exhibited ~50% increased potency com-
pared to 1α,25(OH)2D3, whereas the other 19-nor analogs
had virtually no potency. These results were consistent with
those obtained using rat osteosarcoma ROS17/2.8 cells [27].
19-nor(3β) and 19-nor-22-oxa(1α) inhibit 3H-thymidine
incorporation into HL-60 cells
As shown in Figure 7, treatment of HL-60 cells for 3 days
with 10–7 M 1α,25(OH)2D3 inhibited 3H-thymidine 
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Figure 4
Transition states of asymmetric carbonyl-ene cyclization catalyzed by
(6-Br)-BINOL-Ti complexes. 
Figure 5
Transformation of ene products (3) to singly
dehydroxylated analogs of 19-nor-
1α,25(OH)2D3. Reagents and conditions:
(i) dimethylthexylsilyl chloride (TDSCl),
imidazole, dimethyl formamide (DMF), rt; (ii) Li,
tert-BuOH, NH3, Et2O, –78°C;
(iii) N-chlorosuccinimide (NCS), Me2S,
CH2Cl2, –20°C to rt; (iv) PhPLi, THF, 0°C;
(v) H2O2, THF-H2O, rt; (vi) 12, n-BuLi, THF,
–78°C; (vii) TBAF, THF, rt. 
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incorporation with an efficacy of ~60%, in agreement with a
previous report [27]. Despite extremely low binding affini-
ties for VDR (as reported previously), 10–7 M 19-nor(3β)
and 19-nor-22-oxa(1α) inhibited 3H-thymidine incorpora-
tion with efficacies of ~50% and ~60%, respectively. No
other 19-nor analogs inhibited 3H-thymidine incorporation.
We previously reported that among the 19-nor analogs
tested here, only 19-nor(3β) and 19-nor-22-oxa(1α) bind
VDR in vitro, with ~0.3% and 0.4% affinities compared with
1α,25(OH)2D3, respectively (Figure 6), whereas they have
slightly weaker or comparable potencies for transactivation
of the rat 25-hydroxyvitamin D3-24-hydroxylase gene pro-
moter in a co-transfection-luciferase assay. Both 19-nor
analogs, therefore, appear to inhibit 3H-thymidine incorpo-
ration through a VDR-mediated mechanism in HL-60 cells.
19-nor(3β) and 19-nor-22-oxa(1α) cause HL-60 cells to
accumulate in G0/G1
1α,25(OH)2D3 has been shown to promote cell-cycle arrest
in the G0/G1 phase in a variety of cell lines including
leukemic cells and breast cancer cells [38,39]. To compare
the antiproliferative effects of analogs on HL-60 cell
growth, we assayed cell-cycle distribution of HL-60 cells
treated with 1α,25(OH)2D3 or the 19-nor analogs. Results
from three individual experiments after 72 hours by flow
cytometry of propidium iodide-stained cells are shown in
Table 2. We found that, like 1α,25(OH)2D3, 19-nor(3β)
and 19-nor-22-oxa(1α) caused HL-60 cells to accumulate
in the G0/G1 phase of the cell cycle. The percentages of
HL-60 cells in the S + G2/M phases decreased from 43%
(vehicle-treated cells) to 27% by 1α,25(OH)2D3, to 35% by
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Figure 7
[3H]-Thymidine incorporation into HL-60 cells
treated with either 1α,25(OH)2D3 or the
19-nor-1α,25(OH)2D3 analogs. HL-60 cells
were plated at 106 cells per well in 24-well
plates. 1α,25(OH)2D3 or 19-nor-1α,25(OH)2D3
analogs were added to ethanol vehicle in media
at 4 concentrations, from 10–7–10–10 M. After
3 days, radioactivity incorporated into the cells
was measured by liquid scintillation counter. 
Figure 6
Transcriptional potency of 1α,25(OH)2D3 and
the 19-nor-1α,25(OH)2D3 analogs on a rat
25(OH)D3-24-hydroxylase gene promoter in
transfected HL-60 cells. The cells were
electroplated with a reporter plasmid (pGVB2
vector, Toyo Ink Co., Ltd, Tokyo, Japan)
containing the luciferase gene under the control
of a rat 25(OH)D3-24-hydroxylase promoter
(–291/+9), which has two VDREs, and a pRL-
CMV vector as an internal control. After 48 h
culture with the compounds, cell lysates were
prepared and light production from luciferase
was measured as described in the Materials
and methods section. Luciferase activities
induced by 1α,25(OH)2D3 and its analogs in
HL-60 cells were quantified and represented as
x-fold induction as compared with luciferase
activity observed in the control cells. Results
represent the mean of three experiments
(values in column) and standard errors (vertical
bars) at 10–8 M. The VDR binding affinities of all
analogs were previously reported [27].
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19-nor(3β), and to 37% by 19-nor-22-oxa(1α) at 10–7 M.
There were no significant differences in cell-cycle distrib-
utions of the HL-60 cells treated with the other 19-nor
analogs relative to vehicle-treated cells. These results are
consistent with those from previous 3H-thymidine incor-
poration assays. Thus, the HL-60 cell growth inhibition
exerted by 1α,25(OH)2D3, 19-nor(3β) and 19-nor-22-
oxa(1α) is probably due to inhibition of cellular progres-
sion to G0/G1 + S phases via a VDR-mediated mechanism. 
19-nor(3β) and 19-nor-22-oxa(1α) cause HL-60 cells to
differentiate into monocytes/macrophages
Expression of cell-surface CD11b and CD14 antigens is
one of the major differentiation markers of HL-60 cells to
monocytes/macrophages. As depicted in Figure 8,
1α,25(OH)2D3, 19-nor(3β) and 19-nor-22-oxa(1α) at 10–7 M
significantly increased the number of CD11b antigen-
expressing cells. CD11b antigen expression increased in
both dose- and time-dependent manners in the presence of
1α,25(OH)2D3, 19-nor(3β) or 19-nor-22-oxa(1α) (data not
shown). The other 19-nor analogs did not cause HL-60 cells
to express CD11b antigen over vehicle-treated cells at any
time or dose. 1α,25(OH)2D3 increased the number of CD14
antigen-expressing cells, whereas the 19-nor analogs had
weak or virtually no such potency. Regarding morphological
changes, the HL-60 cells treated with 1α,25(OH)2D3,
19-nor(3β) or 19-nor-22-oxa(1α) became longer and thinner,
giving a macrophage-like appearance. These findings
clearly indicate that both 19-nor(3β) and 19-nor-22-oxa(1α)
can induce differentiation of HL-60 cells along the
macrophage lineage via a VDR-mediated mechanism.
19-nor(1β), 19-nor(3α) and 19-nor-22-oxa(1β) increase the
number of apoptotic HL-60 cells
To clarify whether the inhibitory effects of 1α,25(OH)2D3
and 19-nor analogs on HL-60 cell growth correlate with
their effects on apoptosis, the number of apoptotic HL-60
cells treated with 1α,25(OH)2D3 or 19-nor analogs was
counted and calculated as a percentage of 200 cells scored
in each random fluoromicroscopic field of view. Figure 9
shows that 19-nor(1β), 19-nor(3α) and 19-nor-22-oxa(1β),
but not 1α,25(OH)2D3 or other 19-nor analogs, induced
apoptosis in HL-60 cells. It has been reported that
1α,25(OH)2D3 itself has no apoptosis-stimulating effect
on HL-60 cells, although it has an inhibitory effect on
drug-induced apoptosis in HL-60 cells [40]. Our findings
are consistent with these reports. Surprisingly, 19-nor(1β),
19-nor(3α) and 19-nor-22-oxa(1β), which have unnatural
orientations (1 and 3 epimerization, respectively) of the
hydroxyl groups at the C-1 and C-3 positions in the A-ring,
significantly increased the number of apoptotic HL-60
cells. Moreover, the apoptosis-stimulating potency of
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Table 2
Cell cycle phase distribution in HL-60 cells treated with
1α,25(OH)2D3 or the analogs.
Compound G0/G1 (%) S (%) G2/M (%)
Control 57.27 ± 1.57 33.48 ± 1.26 9.25 ± 0.33
1α,25(OH)2D3 73.20 ± 1.25** 19.27 ± 1.05*** 7.53 ± 0.26*
19-nor(1α) 56.81 ± 1.19** 33.99 ± 1.28*** 9.20 ± 0.10*
19-nor(1β) 56.97 ± 1.43** 34.16 ± 1.07*** 8.88 ± 0.39*
19-nor(3α) 57.18 ± 1.39** 33.99 ± 0.93*** 8.83 ± 0.47*
19-nor(3β) 64.57 ± 0.51* 26.91 ± 1.02* 8.52 ± 0.57*
19-nor-22-oxa(1α) 63.33 ± 0.62* 27.93 ± 0.62* 8.74 ± 0.17
19-nor-22-oxa(1β) 57.92 ± 1.50* 33.58 ± 0.91* 8.50 ± 0.59
19-nor-22-oxa(3α) 59.03 ± 0.83* 31.72 ± 0.71* 9.25 ± 0.29
19-nor-22-oxa(3β) 57.15 ± 1.29* 33.98 ± 1.02* 8.87 ± 0.47
Values sharing the same subscript are significantly different (*< 0.05,
**< 0.01, ***< 0.001).
Figure 8
CD11b- and CD14-antigen-positive cell
numbers appeared from HL-60 cells treated
with either 1α,25(OH)2D3 or the 19-nor-
1α,25(OH)2D3 analogs. HL-60 cells were
grown and plated at 105 cells per well in 24-
well plates as described in the Materials and
methods section. 1α,25(OH)2D3 or the 19-
nor-1α,25(OH)2D3 analogs were added in
ethanol vehicle in media at 10–7 M and
incubation proceeded for 3 days. Cells were
harvested and CD11b and CD14 analyses
using a fluorescence-activated cell sorter
(FACS) were performed.
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19-nor(1β) and 19-nor(3α), which bear natural sidechains,
appears to be greater than that of 19-nor(1β) and
19-nor(3α), which bear 22-oxa type sidechains. It has been
reported that 22-oxa-1α,25(OH)2D3 is more active than
1α,25(OH)2D3 in stimulating monocytic differentiation of
HL-60 cells to macrophages through a VDR-mediated
mechanism [41]. Our findings coupled with previous find-
ings on 22-oxa-1α,25(OH)2D3 suggest that a 22-oxa-type
sidechain functions as an enhancer via a VDR-dependent
mechanism, but as a suppressor in a VDR-nondependent
mechanism. In addition, it is possible that the orientation
of the hydroxyl groups at the C-1 and C-3 positions in the
A-ring of 1α,25(OH)2D3 may be structural motifs responsi-
ble for controlling two signaling pathways, namely a VDR-
dependent mechanism, such as cell differentiation and
transactivation of target genes, and a VDR-nondependent
mechanism, such as apoptosis.
19-nor(1β), 19-nor(3α) and 19-nor-22-oxa(1β) induce DNA
fragmentation in HL-60 cells
Figures 10 and 11 show fluoromicroscopy images of HL-60
cells treated with 1α,25(OH)2D3 or 19-nor analogs using a
Tdt-mediated dUTP nick end-labeling (TUNEL)
method. No apoptotic cells were observed in the vehicle-
or 1α,25(OH)2D3-treated HL-60 cells. Moreover, no apop-
totic cells were observed in the 19-nor analogs bearing 1α-
or 3β-hydroxyl groups in the A-ring. In contrast, the 19-nor
analogs bearing 1β- or 3α-hydroxyl groups in the A-ring
exerted weak, but significant, apoptosis induction.
Figure 12 shows that the 19-nor analogs bearing 1β- or
3α-hydroxyl groups in the A-ring (but not vehicle,
1α,25(OH)2D3 or other 19-nor analogs) caused DNA frag-
mentation, which is typical of apoptosis. DNA ladders
were prominent when cells were treated for 120 h. In addi-
tion, fragmentation of DNA by 19-nor(1β) and 19-nor(3α)
was more prominent than by 19-nor-22-oxa(1β) and 19-nor-
22-oxa(3α), suggesting that the 19-nor analogs that have
natural sidechains induce apoptosis more strongly than
those with 22-oxa-type sidechains.
We previously reported that two novel 19-nor-
1α,25(OH)2D3 analogs, 19-nor(3β) and 19-nor-22-oxa(1α),
are comparable to 1α,25(OH)2D3 in stimulating rat
25-hydroxyvitamin D3-24-hydroxylase gene promoter
activity in transfected rat osteosarcoma ROS 17/2.8 cells,
regardless of their extremely low binding affinities for
VDR (0.3% and 0.4%, respectively, compared with that of
1α,25(OH)2D3) [27]. We also found that both analogs have
significant antiproliferative activity on HL-60 cells. These
results suggested that in 1α,25(OH)2D3 molecules, singly
1α- or 3β-hydroxylated A-rings without the C-19 moiety
are key structural motifs for expression of vitamin D action
via a VDR-mediated signaling pathway in target cells.
To clarify other possible roles of these hydroxyl groups,
we further investigated the biological activities of 19-nor
analogs in HL-60 cells with respect to differentiation, cell-
cycle distribution and induction of apoptosis. McCarthy
et al. [42] previously reported that 1α,25(OH)2D3 inhibits
proliferation of HL-60 cells and promotes differentiation
of HL-60 cells to monocyte/macrophage-like cells without
inducing apoptosis. In agreement with this study, we
found that treating HL-60 cells with 1α,25(OH)2D3
induced monocytic differentiation and cell-cycle arrest in
the G0/G1 phase (Figure 8 and Table 2). Like
1α,25(OH)2D3, 19-nor(3β) and 19-nor-22-oxa(1α) also
induced cell-growth arrest and differentiation without
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Figure 9
Number of apoptotic cells from HL-60 cells
treated with 1α,25(OH)2D3 or the 19-nor-
1α,25(OH)2D3 analogs. HL-60 cells were
grown and plated at 105 cells per well in
24-well plates as described in the Materials
and methods section. 1α,25(OH)2D3 or
19-nor-1α,25(OH)2D3 analogs were added to
ethanol vehicle in media at 10–7 M, and
incubation proceeded for 120 h. In duplicate
cultures, changes in nuclear morphology that
were characteristic of apoptosis were
quantified by staining with the DNA-specific
fluorochrome bisbenzimide (Hoechst 33258),
and data are expressed as percentages of
apoptotic cells. Cells with chromatin
condensation in the nucleus into three or
more fragments were considered to be
apoptosed. A minimum of 200 cells in each
field were scored. The data represent two
independent determinations from three
separate experiments.
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inducing apoptosis, although they were much less potent
(Figures 8–12 and Table 2). In contrast, 19-nor(1β),
19-nor(3α) and 19-nor-22-oxa(1β), which completely lack
VDR binding potency [27] and possess an epimerized
hydroxyl group at C-1 or C-3 in the A-ring, all induced
apoptosis without inducing cell-growth arrest and differ-
entiation (Figures 8–12 and Table 2). These findings
suggest that in 19-nor-1α,25(OH)2D3 analogs both the
1α-hydroxyl and 3β-hydroxyl groups in the A-ring are
structural motifs for the induction of monocytic differenti-
ation in HL-60 cells, but not apoptosis, and conversely,
both the 1β-hydroxyl and 3α-hydroxyl groups in the
A-ring are structural motifs for the induction of apoptosis,
but not monocytic differentiation. It is also interesting that
an analog with the combination of 22-oxa sidechain and
3α-hydroxyl group appears to have extremely weak VDR-
binding affinity and induces monocytic differentiation in
HL-60 cells, but not apoptosis. This is the first report
demonstrating selective control of apoptosis and mono-
cytic differentiation in HL-60 cells that is dependent on
the stereochemistry of hydroxyl groups at the C-1 and C-3
positions in the A-ring of 19-nor-1α,25(OH)2D3 analogs.
A number of vitamin D analogs, including 1α,25(OH)2D3
itself, are known to induce apoptosis in many subtypes of
breast cancer and prostate cancer cell lines [43,44]. It has
been suggested that 1α,25(OH)2D3 prevents drug-induced
apoptosis in HL-60 cells through increased expression of
the anti-apoptosis genes Bcl-XL and Mcl-1 [40]. To our
knowledge, however, few reports have demonstrated apop-
tosis induced by 1α,25(OH)2D3 and its active analogs in
HL-60 cells [45]. Because HL-60 cells are known to be
highly susceptible to 1α,25(OH)2D3 and can be differenti-
ated to monocyte/macrophage-like cells, it is possible that
the differentiation-inducing activity of 1α,25(OH)2D3 is
much greater than its apoptotic activity, therefore masking
its apoptotic activity. In contrast, 1α,25(OH)2D3 is known
to be highly anti-proliferative in breast cancer cell line
MCF-7 and induces apoptosis via cell-cycle arrest [46]. Our
singly dehydroxylated A-ring analogs provided useful
probes to assess the biological roles of hydroxyl groups
independently and try to resolve some of these conflicting
observations. It appears that the stereochemistry of these
hydroxyl groups determines whether an analog induces
differentiation or apoptosis. To test this hypothesis, further
investigations are needed to elucidate the apoptotic effects
of 19-nor-1α,25(OH)2D3 analogs on MCF-7 cells. Although
the stereochemistry of hydroxyl groups at C-1 and C-3 in
the A-ring provides the key structural motifs responsible
for both biological activities, it is unclear how the 19-nor-
1α,25(OH)2D3 analogs mediate these unique biological
responses. It has been reported that 1α,25(OH)2D3 pro-
tects HL-60 cells from drug-induced apoptosis [40], and
also reduces the apoptotic effects of retinoid N-(4-hydrox-
yphenyl)-all-trans-retinamide [47]. Because antisense inhi-
bition of VDR expression induces apoptosis in U937 cells
[48], it has been suggested that the anti-apoptotic effect of
1α,25(OH)2D3 is mediated via binding to VDR. It is likely,
therefore, that 19-nor(3β) and 19-nor-22-oxa(1α), which
possess VDR binding affinities even at extremely low con-
centrations, might exert anti-apoptotic effects on HL-60
cells similar to 1α,25(OH)2D3; further investigation is
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Figure 10
Apoptotic cells from HL-60 cells treated with either vehicle,
1α,25(OH)2D3 or 19-nor-1α,25(OH)2D3 analogs. HL-60 cells were
grown and plated at 105 cells per well in 24-well plates as described
in the Materials and methods section. 1α,25(OH)2D3 or
19-nor-1α,25(OH)2D3 analogs were added to ethanol vehicle in media
at 10–7 M and incubation proceeded for 120 h. Cells were stained by
the TUNEL method and nuclei were visualized by fluorescence
microscopy. Green fluorescent-labeled cells are TUNEL positive cells.
Figure 11
Apoptotic cells from HL-60 cells treated with either vehicle,
1α,25(OH)2D3 or 19-nor-22-oxa-1α,25(OH)2D3 analogs. HL-60 cells
were grown and plated at 105 cells per well in 24-well plates as
described in the Materials and methods section. 1α,25(OH)2D3 or
19-nor-1α,25(OH)2D3 analogs were added to ethanol vehicle in media
at 10–7 M and incubation proceeded for 120 h. Cells were stained by
the TUNEL method and nuclei were visualized by fluorescence
microscopy. Green fluorescent-labeled cells are TUNEL positive cells.
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needed in this matter. In contrast, 19-nor(1β), 19-nor(3α)
and 19-nor-22-oxa(1β), which are completely inactive in
inducing differentiation and inhibiting proliferation of
HL-60 cells due to a lack of VDR binding potency, induce
apoptosis in HL-60 cells. Because they do not bind to the
VDR, it is clear that their apoptotic effects on HL-60 cells
are not mediated by a classical VDR-mediated signalling
pathway. At present, we do not have any explanation for
the mechanism by which these analogs induce apoptosis in
HL-60 cells. Recently, several lines of evidence have been
presented concerning the induction of apoptosis in HL-60
cells. It has been suggested that apoptotic agents release
cytochrome C, an oxidant, from the mitochondria, which
then activates caspase-3 (CPP32), which in turn cleaves the
45 kDa subunit of the DNA fragmentation factor (DFF) to
produce an active factor that triggers apoptotic DNA frag-
mentation [49]. Enigmatically, 1α,25(OH)2D3 appears to
increase the mitochondrial anti-apoptotic protein MCL-1
and proliferation-associated protein RAF-1, which in turn
reduces the release of mitochondrial cytochrome C and
prevents HL-60 cells from undergoing apoptosis [40]. This
cytoprotective effect of 1α,25(OH)2D3 appears to be medi-
ated via the binding of 1α,25(OH)2D3 to VDR; it is
unlikely, therefore, that 19-nor(1β), 19-nor(3α) and 19-nor-
22-oxa(1β) use this signaling pathway. Ceramide, a sphin-
golipid breakdown product, is known to be a potent
inducer of apoptosis in HL-60 cells. It has been shown that
1α,25(OH)2D3 activates sphingosine kinase, which in turn
converts ceramide to sphingosin-1-phosphate (SPP) and
prevents HL-60 cell ceramide-induced apoptosis [50].
There was a correlation between the time course and dose
response of activation of sphingosin kinase by
1α,25(OH)2D3 and protection from apoptosis. This cyto-
protective effect of 1α,25(OH)2D3 is also dependent on
VDR binding potency. The apoptotic effects of 19-nor
analogs may, therefore, occur via this mechanism. In the
present study, the apoptosis of HL-60 cells was induced by
several 19-nor-1α,25(OH)2D3 analogs, but not by
1α,25(OH)2D3, suggesting that these analogs have a quali-
tative difference in biological activity compared with
1α,25(OH)2D3. Because these analogs lack the ability to
bind VDR, it is reasonable to suggest that these analogs
use unknown receptors or recognize unknown enzymes
that mediate a novel set of gene expression or metabolism
that regulates apoptosis. Further investigation, such as the
identification of candidates involved in the induction of
apoptosis in HL-60 cells, will help us to understand the
biological roles of each hydroxyl group and the exocyclic
methylene moiety in the A-ring of 1α,25(OH)2D3. 
In summary, we have identified a novel series of 19-nor-
1α,25(OH)2D3 analogs with selective control activities for
apoptosis and monocytic differentiation of HL-60 cells
in vitro. These interesting analogs will be studied for their
ability to regulate target gene expressions in vitro and
control myeloid leukemias in vivo.
Significance
1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3), the active
form of vitamin D3, acts through the vitamin D receptor
to elicit a number of activities. Because these activities
include differentiation, proliferation and apoptosis in
malignant cells, 1α,25(OH)2D3 or its derivatives could
be useful for treating cancer. There is very little known
about the various structural motifs of 1α,25(OH)2D3
that are responsible for modulating these different activi-
ties, however. In order to investigate these motifs, we
synthesized a series of singly dehydroxylated 19-nor-
1α,25-dihydroxyvitamin D3 A-ring analogs in a catalytic
asymmetric fashion and investigated their biological
activities in leukemia HL-60 cells. To our surprise, the
analogs could be clearly divided into two groups. A-ring
analogs that contain 1α-hydroxy or 3β-hydroxy groups
induce cellular differentiation and analogs that bear
1β-hydroxy or 3α-hydroxy groups are potent stimulators
of apoptosis. These observations should help in the
design and development of therapeutic agents for treat-
ing leukemia and other cancers.
Materials and methods
Chemicals
1α,25(OH)2D3 was purchased from Solvay-Duphar Co., Weesp, The
Netherlands. The 19-nor-1α,25(OH)2D3 analogs included 19-nor-3β-
dehydroxy-1α,25(OH)2D3 [19-nor(1α)], 19-nor-3β-dehydroxy-
1β,25(OH)2D3 [19-nor(1β)], 19-nor-3-epi-25(OH)D3 [19-nor(3α)],
and 19-nor-25(OH)D3 [19-nor(3β)]. The singly dehydroxylated A-ring
analogs of 19-nor-22-oxa-1α,25(OH)2D3 included 19-nor-3β-dehy-
droxy-22-oxa-1α,25(OH)2D3 [19-nor(1α)], 19-nor-3β-dehydroxy-22-
oxa-1β,25-(OH)2D3 [19-nor(1β)], 19-nor-3-epi-22-oxa-25(OH)D3
[19-nor(3α)], and 19-nor-22-oxa-25(OH)D3 [19-nor(3β)]. All analogs
were dissolved in aldehyde-free absolute ethanol as stock solutions
at 10–4 M and stored at –35°C protected from light.
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Figure 12
DNA fragmentation assay of apoptosis in HL-60 cells treated with
either vehicle, 1α,25(OH)2D3 or 19-nor-1α,25(OH)2D3 analogs. HL-60
cells were grown and plated at 105 cells per well in 24-well plates as
described in the Materials and methods section. 1α,25(OH)2D3 or
19-nor-1α,25(OH)2D3 analogs were added to ethanol vehicle in media
at 10–7 M and incubation proceeded for 120 h. Cells were harvested
and fragmentation of chromosomal DNA was assessed by
electrophoresis on a 2.0% agarose gel. Lane 1, vehicle (ethanol);
lane 2, 1α,25(OH)2D3; lane 3, 19-nor(1α); lane 4, 19-nor(1β); lane 5,
19-nor(3α); lane 6, 19-nor(3β); lane 7, 19-nor-22-oxa(1α); lane 8, 19-
nor-22-oxa(1β), lane 9, 19-nor-22-oxa(3α); lane 10, 19-nor-22-oxa(3β).
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Transcriptional activity on a rat 25(OH)D3-24-hydroxylase
gene promoter in transfected HL-60 cells
Human promyelocytic leukemic HL-60 cells were obtained from
Y. Seino of the Okayama University School of Medicine. The cells were
maintained in continuous culture in RPMI-1640 medium (Nissui Seiyaku
Co., Ltd, Tokyo, Japan) supplemented with 10% dextran-coated char-
coal-treated fetal calf serum (Gibco BRL, Grand Island, NY, USA), and
kanamycin (0.06 mg/ml; Sigma) at 37°C in a humidified atmosphere of
5% CO2 in air. Cells (1×107) were suspended in 800 µl of the serum
free medium and electropolated with 10 µg luciferase reporter plasmid
(pGVB2 vector, Toyo Ink Co., Ltd, Tokyo, Japan) inserted with a rat
25(OH)D3-24-hydroxylase gene promoter (–291/+9) including the two
VDREs and 5 µg of the pRL-CMV vector (Toyo Ink Co., Ltd) as an inter-
nal control using GENE PULSER II (Bio-Rad Laboratories, Hercules,
CA). Cells were cultured for 24 h in the RPMI1640 medium containing
of 10% FCS at 37°C in a humidified atmosphere of 5% carbon dioxide
in air. After 24 h, cells were seeded at 2105 cells/well in 24-well plates,
and incubated for 2 days with between 10–8 M of 1α,25(OH)2D3 or an
analog. The luciferase activities of the cell lysates were measured with a
luciferase assay system (Toyo Ink Co., Ltd), according to the manufac-
turer’s instructions. Transactivation measured by luciferase activity was
standardized with the luciferase activity of the same cells determined by
the Sea Pansy luciferase assay system as a control (Toyo Ink Co., Ltd).
Each set of experiments was repeated at least 3 ×, and the results are
presented in terms of fold-induction as means standard errors.
HL-60 cells and synchronization of cell cycle at S phase by
excess amounts of thymidine
The doubling time of HL-60 cells was ~24 h. The cells were synchronized
at S phase by the following procedure: cells (4105 cells/ml) were cultured
in 30 ml of RPMI-1640 medium for 24 h and subsequently cultured for
16 h in RPMI-1640 medium supplemented with 2.5 mM thymidine. After
washing the cells with Ca,Mg-free phosphate buffered saline (PBS(–))
twice, the synchronization of cell cycle by the same manner was repeated,
and the cells thus obtained were used in the following experiments. 
3H-thymidine incorporation assay
Cells (105 cells/well) were placed in 24-well tissue culture plates, and
cultured for 3 days with or without different concentrations of
1α,25(OH)2D3 or analogs. After washing with RPMI-1640 medium, the
cells were incubated with [methyl-3H]-thymidine (1 mCi/ml) in RPMI-
1640 for 1 h under the same conditions and subsequently incubated
for 5 min at room temperature in PBS(–) containing 100 mM unlabeled
thymidine. Cells were dissolved in 0.1 M NaOH, and aliquots were
taken for measuring radioactivity in a liquid scintillation counter. 
Flow cytometry
Cells (105 cells/well) were placed in 24-well tissue culture plates and
cultured for 3 days in RPMI-1640 medium with 10–7 M 1α,25(OH)2D3
or analogs under the same conditions as above. To reduce the effects
of contact inhibition, control cells were adjusted to 60–70% conflu-
ency at the time of FACS analysis. Each group of cells was collected
and washed with PBS(–) once. Then, the cells were resuspended in
PBS(–) containing 0.2% Triton-X and 100 µg RNase, and incubated at
37°C for 1 h. Cells were washed with PBS(–) and incubated with
0.5 ml of DNA-staining solution containing propidium iodide (50 µg/ml)
at 4°C for 20 min. The cells were analysed with a flow cytometer
euipped with an argon laser (488 nm, Becton Dickinson FACScan)
and cell cycle distribution was analyzed by ModiFiT LT(Verity). Experi-
ments were repeated 3 ×.
Cell surface antigen expression analysis
Cells (105 cells/well) were placed in 24-well tissue culture plates, and
cultured for 3 days in RPMI-1640 medium with 10–7 M 1α,25(OH)2D3 or
analogs under the same conditions as above. Each group of cells was
then collected and washed with PBS(–) once. Then, the cells
(2105 cells) were resuspended in 100 µl diluent solution containing 1%
bovine serum albumin (BSA) and 1% sodium azide and incubated with
10 µl human monoclonal FITC conjugated CD11b antibody (Sigma,
USA) and 10 µl human monoclonal PE conjugated CD14 antibody
(Sigma, USA) for 30 min at room temperature without light. The cells
were washed once with Diluent solution and then fixed in 300 µl of
PBS(–) containing 2% paraformaldehyde. Fluorescence was detected
on a Becton Dickinson FACScan at excitation wavelength of 490 nm
and emission wavelength of 520 nm. Results were recorded as the mean
fluorescence index, which is the product of the % fluorescence and the
mean fluorescence intensity, with 104 cells being counted per treatment. 
Nuclear staining assay
Cells (105 cells/well) were placed in 24-well tissue culture plates, and
cultured for 120 h in RPMI-1640 medium with 10–7 M 1α,25(OH)2D3
or analogs under the same conditions as above. Each group of cells
was then collected and washed with PBS(–) once. The cells were fixed
with 1% glutaraldehyde in PBS(–) for 30 min, then washed with
PBS(–). The preparations were suspended in PBS(–) and stained with
1 mM Hoechst33258 (Calbiochem) in PBS(–) for 10 min. The cells
were viewed under an OLYMPUSIX70 microscope. Condensed and
fragmented nuclei were counted, and percentages were calculated.
Three random fields of view were observed with a minimum number of
200 cells scored per field. 
Tdt-mediated dUTP nick end-labeling (TUNEL) assay
Cells (105 cells/well) were placed in 24-well tissue culture plates, and
cultured for 120 h in RPMI-1640 medium with 10–7 M 1α,25(OH)2D3
or analogs under the same conditions as above. Each group of cells
was then collected and washed with PBS(–) once. The cells were fixed
with 4% paraformaldehyde in PBS(–) for 30 min and then washed with
PBS(–). DNA fragmentation was detected by the In Situ Apoptosis
Detection Kit (Takara Shuzo Co., Ltd, Japan) according to the manufac-
turer’s protocol. This assay labels individual cells undergoing apoptosis
by terminal transferase-mediated addition of fluorescein dUTP at DNA
strand breaks. Following washing and mounting, cells were viewed
under an OLYMPUS IX70 microscope and photographed.
DNA fragmentation assay
For assessment of quantitative DNA fragmentation (laddering), DNA
was isolated from cells of each culture, and was examined for fragmen-
tation. DNA was electrophoresed in a 2% agarose gel that was stained
with ethidium bromide for observation under ultraviolet light [51,52].
Statistics
The results are expressed as means SEM. A paired or unpaired Stu-
dent’s t test was used to determine the significance of difference; a
value of P < 0.05 was considered significant.
Supplementary material
Supplementary material including synthesis of analogs is available at
http://current-biology.com/supmat/supmatin.htm.
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